{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Partial+Onset+Seizures", "query": { "condition": "Refractory Partial Onset Seizures" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Partial+Onset+Seizures&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T07:34:31.846Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00152503", "title": "Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epilepsy, Partial" ], "interventions": [ { "name": "Seletracetam (UCB44212)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Pharma SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 59, "start_date": "2005-08-31", "completion_date": "2006-05-12", "has_results": true, "last_update_posted_date": "2023-09-07", "last_synced_at": "2026-06-26T07:34:31.846Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • St. Petersburg, Florida + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00152503" }, { "nct_id": "NCT00175890", "title": "A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy, Partial" ], "interventions": [ { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "4 Years", "sex": "ALL", "summary": "1 Month to 4 Years" }, "enrollment_count": 116, "start_date": "2004-10", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2020-10-01", "last_synced_at": "2026-06-26T07:34:31.846Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00175890" }, { "nct_id": "NCT00152451", "title": "Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epilepsy, Partial" ], "interventions": [ { "name": "Seletracetam (ucb 44212)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB S.A. - Pharma Sector", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 31, "start_date": "2005-05-19", "completion_date": "2006-05-03", "has_results": true, "last_update_posted_date": "2024-03-29", "last_synced_at": "2026-06-26T07:34:31.846Z", "location_count": 7, "location_summary": "Little Rock, Arkansas • San Francisco, California • Stanford, California + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00152451" }, { "nct_id": "NCT06309966", "title": "Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Focal Epilepsy" ], "interventions": [ { "name": "BHV-7000", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 390, "start_date": "2024-05-13", "completion_date": "2026-05", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-06-26T07:34:31.846Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06309966" }, { "nct_id": "NCT00772603", "title": "Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsies, Partial" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "2400mg SPN-804", "type": "DRUG" }, { "name": "1200mg SPN-804", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 366, "start_date": "2008-11", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2014-02-11", "last_synced_at": "2026-06-26T07:34:31.846Z", "location_count": 23, "location_summary": "Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00772603" }, { "nct_id": "NCT01713946", "title": "A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberous Sclerosis Complex-associated Refractory Seizures" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antiepileptic drug (1 to 3 only)", "type": "DRUG" }, { "name": "open label RAD001 (only used for post-extension phase)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "2 Years to 65 Years" }, "enrollment_count": 366, "start_date": "2013-04-29", "completion_date": "2017-10-25", "has_results": true, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-06-26T07:34:31.846Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01713946" }, { "nct_id": "NCT00448539", "title": "Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Refractory Partial Onset Seizures" ], "interventions": [ { "name": "Rufinamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 286, "start_date": "2007-03-15", "completion_date": "2010-05-14", "has_results": true, "last_update_posted_date": "2019-11-22", "last_synced_at": "2026-06-26T07:34:31.846Z", "location_count": 27, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Bradenton, Florida + 22 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Loxahatchee Groves", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448539" }, { "nct_id": "NCT00699972", "title": "Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Refractory Partial Seizures" ], "interventions": [ { "name": "E2007 (perampanel)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "12 Years to 99 Years" }, "enrollment_count": 390, "start_date": "2008-04-30", "completion_date": "2010-10-19", "has_results": true, "last_update_posted_date": "2020-01-10", "last_synced_at": "2026-06-26T07:34:31.846Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00699972" }, { "nct_id": "NCT06377930", "title": "Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Focal Onset Seizures" ], "interventions": [ { "name": "RAP-219", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rapport Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2024-10-10", "completion_date": "2025-09-26", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-06-26T07:34:31.846Z", "location_count": 12, "location_summary": "New Haven, Connecticut • Boise, Idaho • Indianapolis, Indiana + 7 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boise", "state": "Idaho" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06377930" }, { "nct_id": "NCT00235755", "title": "Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Seizures" ], "interventions": [ { "name": "Retigabine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 539, "start_date": "2005-12", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2017-04-21", "last_synced_at": "2026-06-26T07:34:31.846Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Dallas, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00235755" } ] }